Marshall Wace LLP Sells 26,313 Shares of NeuroPace, Inc. (NASDAQ:NPCE)

Marshall Wace LLP lowered its stake in NeuroPace, Inc. (NASDAQ:NPCE) by 45.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,045 shares of the company’s stock after selling 26,313 shares during the quarter. Marshall Wace LLP owned approximately 0.11% of NeuroPace worth $242,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. XTX Topco Ltd increased its stake in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares during the period. Acadian Asset Management LLC increased its stake in shares of NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after buying an additional 21,703 shares during the period. Rhumbline Advisers acquired a new position in shares of NeuroPace in the second quarter valued at approximately $111,000. Financial Advocates Investment Management increased its stake in shares of NeuroPace by 50.0% in the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after buying an additional 5,000 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in NeuroPace during the 2nd quarter valued at approximately $257,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Morgan Stanley decreased their target price on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Wells Fargo & Company decreased their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.00.

NeuroPace Price Performance

NeuroPace stock opened at $6.61 on Friday. The stock has a market capitalization of $190.16 million, a price-to-earnings ratio of -5.55 and a beta of 1.78. NeuroPace, Inc. has a 52-week low of $5.73 and a 52-week high of $18.15. The stock’s 50 day moving average price is $7.11 and its two-hundred day moving average price is $8.62. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The firm had revenue of $19.26 million for the quarter, compared to analysts’ expectations of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.36) EPS. On average, equities analysts predict that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.